← Product Code [DSH](/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSH) · K090363 # ZIO PATCH, MODEL Z100 (K090363) _iRhythm Technologies, Inc. · DSH · May 8, 2009 · Cardiovascular · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSH/K090363 ## Device Facts - **Applicant:** iRhythm Technologies, Inc. - **Product Code:** [DSH](/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSH.md) - **Decision Date:** May 8, 2009 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 870.2800 - **Device Class:** Class 2 - **Review Panel:** Cardiovascular ## Indications for Use The Zio™ patch is a prescription only single patient use, continuous recording ECG monitor that can be worn for up to 14 days. It is indicated for use on patients who experience transient symptoms such as syncope, palpitations, shortness of breath, or chest pains. ## Device Story Zio™ patch is a single-patient-use, wearable, continuous ECG monitor. Device records cardiac electrical activity for up to 14 days. Worn by patients experiencing transient symptoms like syncope, palpitations, shortness of breath, or chest pain. After the monitoring period, the patch is returned for data analysis. Healthcare providers use the resulting ECG reports to evaluate cardiac rhythms and inform clinical decision-making regarding potential arrhythmias. The device facilitates long-term ambulatory monitoring, increasing the likelihood of capturing transient cardiac events compared to shorter-duration Holter monitors. ## Clinical Evidence No clinical data provided in the document; substantial equivalence is based on technological characteristics and intended use. ## Technological Characteristics Single-patient-use wearable ECG monitor. Continuous recording capability for up to 14 days. Form factor is a patch. Intended for ambulatory use. ## Regulatory Identification A medical magnetic tape recorder is a device used to record and play back signals from, for example, physiological amplifiers, signal conditioners, or computers. ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows a black and white logo for the U.S. Department of Health and Human Services. The logo features the text "U.S. HEALTH & HUMAN SERVICES. USA" arranged in an arc. To the right of the text is a stylized graphic with three curved lines. ## DEPARTMENT OF HEALTH & HUMAN SERVICES MAY - 8 2009 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 iRhythm Technologies, Inc. c/o Mr. William H. Righter Director of Product Development 650 Townsend Street, Suite 380 San Francisco, CA 94103 Re: K090363 Trade/Device Name: Zio™ patch Model Z100 Regulation Number: 21 CFR 870.2800 Regulation Name: Medical Magnetic Tape Recorder Regulatory Class: Class II (two) Product Codes: DSH Dated: February 6, 2009 Received: February 13, 2009 Dear Mr. Righter: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ પુ ## Page 2 - Mr. William H. Righter Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, 37 Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ | Page 1 of 1 | | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------| | iRhythm Logo | | | INDICATIONS FOR USE STATEMENT | | | 510(k) Number: | K090363 | | Device Names: | Zio TM patch | | Indications for Use:. | | | The Zio TM patch is a prescription only single patient use, continuous recording ECG monitor that can be worn for up to 14 days. It is indicated for use on patients who experience transient symptoms such as syncope, palpitations, shortness of breath, or chest pains. | | | | | | Prescription Use
(Part 21 CFR 801 Subpart D) | X | | | AND/OR | | | Over-The-Counter Use (21 CFR 801 Subpart C) | | (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) | | | | | | | Concurrence of CDRH, Office of Device Evaluation (ODE) | | | | | (Division Sign-Off) | | | Division of Cardiovascular Devices | | | 510(k) Number | K090363 | | | | | | 650 Townsend Street, Suite 380 San Francisco, CA 94103 (415) 632-5700 (415) 632-5701 www.irhythmtech.com | દર્ભાગના પાક --- **Source:** [https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSH/K090363](https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSH/K090363) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com